Alzheimer’s disease

Legacy of Leaded Gasoline: New Evidence Links Childhood and Adult Exposure to Cognitive Impairment in Older Adults

By MedXY 07/30/2025

Recent studies confirm that both childhood and adult lead exposure, especially from gasoline and industrial sources, are associated with increased risk for cognitive decline and dementia in later life.

Clinical Updates Wellness & Lifestyle

Demographic Data Gaps in FDA Authorization of AI-Based Devices for Alzheimer’s Disease and Related Dementias

By MedXY 07/30/2025

Limited demographic data transparency in FDA-authorized AI devices for Alzheimer’s may hinder equitable care and generalizability, highlighting a crucial need for improved dataset representativeness and regulatory oversight.

Clinical Updates Wellness & Lifestyle

Walking and Dietary Interventions Offer Cognitive Protection in APOE ε4 Carriers: New Evidence from Longitudinal and Multinational Trials

By MedXY 07/30/2025

Regular walking and lifestyle interventions slow cognitive decline, especially in APOE ε4 carriers at heightened Alzheimer’s risk, with effects pronounced in women. Evidence underscores the value of simple activity and healthy diet for at-risk older adults.

Clinical Updates Medical News

Lecanemab in Community Practice: Real-World Safety and Efficacy for Early Alzheimer’s Disease

By MedXY 07/29/2025

Community-based data suggest lecanemab is safe and effective for early-stage Alzheimer’s, with manageable ARIA rates and infusion reactions, particularly in ApoE4 noncarriers.

Clinical Updates Medical News

Alzheimer’s Association Releases First Clinical Guidelines for Blood-Based Biomarkers: Implications for Diagnosis and Practice

By MedXY 07/29/2025

New Alzheimer’s Association guidelines endorse blood-based biomarkers as diagnostic adjuncts, not standalone tests, emphasizing rigorous clinical evaluation and high test accuracy.